Effects of dietary components on high-density lipoprotein measures in a cohort of 1,566 participants

Nutrition and Metabolism

Volumn 11, Issue 1, 2014, Pages

  Kim, Daniel Seung ^a   Burt, Amber A ^a   Ranchalis, Jane E ^a   Jarvik, Leah E ^a   Eintracht, Jason F ^b   Furlong, Clement E ^a   Jarvik, Gail P ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Alcohol; Apolipoprotein A1; Cardiovascular disease; Fatty acids; Folate; Food frequency questionnaire; HDL; HDL subfractions; HDL 2; HDL 3; HDL C; Magnesium

Indexed keywords

APOLIPOPROTEIN A1; ASCORBIC ACID; FOLIC ACID; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; MYRISTIC ACID; TRACE ELEMENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CARBOHYDRATE DIET; CARBOHYDRATE INTAKE; CAROTID ARTERY DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DIETARY FIBER; DIETARY INTAKE; FEMALE; FOOD FREQUENCY QUESTIONNAIRE; HUMAN; IRON INTAKE; MAGNESIUM INTAKE; MAJOR CLINICAL STUDY; MALE; PROTEIN INTAKE; SMOKING;

EID: 84908409438     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-11-44     Document Type: Article

References (58)

1. Castelli WP: Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J 1983, 106:1191-1200.
2. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
3. Barter PJ, Barter PJ, Caulfield M, Caulfield M, Eriksson M, Eriksson M, Grundy SM, Grundy SM, Kastelein JJP, Kastelein JJP, Komajda M, Komajda M, Lopez-Sendon J, Lopez-Sendon J, Mosca L, Mosca L, Tardif J-C, Tardif J-C, Waters DD, Waters DD, Shear CL, Shear CL, Revkin JH, Revkin JH, Buhr KA, Buhr KA, Fisher MR, Fisher MR, Tall AR, Tall AR, et al: Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med 2007, 357:2109-2122.
4. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart AF, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, et al: Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet 2012, 380:572-580.
5. Mackey RH, Greenland P, Goff DC, Lloyd-Jones D, Sibley CT, Mora S: High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2012, 60:508-516.
6. Asztalos BF, Tani M, Schaefer EJ: Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011, 22:176-185.
7. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ: Distribution of ApoA-I-Containing HDL Subpopulations in Patients With Coronary Heart Disease. Arterioscler Thromb Vasc Biol 2000, 20:2670-2676.
8. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, Brown GB, Schaefer EJ: Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003, 23:847-852.
9. Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:1881-1888.
10. Bergmeier C, Siekmeier R, Gross W: Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 2004, 50:2309-2315.
11. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN: Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991, 86:193-199.
12. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
13. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG: Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
14. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE: Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype. Arterioscler Thromb Vasc Biol 2000, 20:2441-2447.
15. Mackness MI, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135.
16. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991, 286:152-154.
17. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998, 101:1581-1590.
18. Kim DS, Marsillach J, Furlong CE, Jarvik GP: Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics 2013, 14:1495-1515.
19. Kim DS, Burt AA, Rosenthal EA, Ranchalis JE, Eintracht JF, Hatsukami TS, Furlong CE, Marcovina S, Albers JJ, Jarvik GP: HDL-3 is a Superior Predictor of Carotid Artery Disease in a Case-control Cohort of 1725 Participants. J Am Heart Assoc 2014, 3(3):e000902. doi:10.1161/JAHA.114.000902.
20. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, Margolin S, Rieder M, Nickerson D, Schellenberg GD: Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 2003, 23:1465-1471.
21. Kim DS, Burt AA, Ranchalis JE, Richter RJ, Marshall JK, Eintracht JF, Rosenthal EA, Furlong CE, Jarvik GP: Additional Common Polymorphisms in the PON Gene Cluster Predict PON1 Activity but Not Vascular Disease. J Lipids 2012, 2012:476316.
22. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL: AHA Dietary Guidelines: Revision 2000: A Statement for Healthcare Professionals From the Nutrition Committee of the American Heart Association. Circulation 2000, 102:2284-2299.
23. Lichtenstein AH: Diet and Lifestyle Recommendations Revision 2006: A Scientific Statement From the American Heart Association Nutrition Committee. Circulation 2006, 114:82-96.
24. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. The Lancet 1994, 343:1454-1459.
25. Fung TT, Chiuve SE, McCullough ML, Rexrode KM, Logroscino G, Hu FB: Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med 2008, 168:713-720.
26. Carter SJ, Roberts MB, Salter J, Eaton CB: Relationship between Mediterranean Diet Score and atherothrombotic risk: findings from the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Atherosclerosis 2010, 210:630-636.
27. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE: Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002, 22:1329-1333.
28. Kim DS, Burt AA, Ranchalis JE, Richter RJ, Marshall JK, Nakayama KS, Jarvik ER, Eintracht JF, Rosenthal EA, Furlong CE, Jarvik GP: Dietary cholesterol increases paraoxonase 1 enzyme activity. J Lipid Res 2012, 53:2450-2458.
29. Kim DS, Maden SK, Burt AA, Ranchalis JE, Furlong CE, Jarvik GP: Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects. Lipids Health Dis 2013, 12:183.
30. Bachorik PS, Albers JJ: Precipitation methods for quantification of lipoproteins. Methods Enzymol 1986, 129:78-100.
31. Marcovina SM, Albers JJ, Henderson LO, Hannon WH: International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993, 39:773-781.
32. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC: Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol 1992, 135:1114-1126. discussion 1127-36.
33. Hunter DJ, Hunter DJ, Rimm EB, Rimm EB, Sacks FM, Sacks FM, Stampfer MJ, Stampfer MJ, Colditz GA, Colditz GA, Litin LB, Litin LB, Willett WC, Willett WC: Comparison of measures of fatty acid intake by subcutaneous fat aspirate, food frequency questionnaire, and diet records in a free-living population of US men. Am J Epidemiol 1992, 135:418-427.
34. Willett W, Stampfer M, Chu NF, Spiegelman D, Holmes M, Rimm E: Assessment of questionnaire validity for measuring total fat intake using plasma lipid levels as criteria. Am J Epidemiol 2001, 154:1107-1112.
35. Dixon WJ, Tukey JW: Approximate behavior of the distribution of Winsorized t (Trimming/Winsorization 2). Technometrics 1968, 10:83-98.
36. Pritchard JK, Stephens M, Donnelly P: Inference of population structure using multilocus genotype data. Genetics 2000, 155:945-959.
37. Rao MN, Marmillot P, Gong M, Palmer DA, Seeff LB, Strader DB, Lakshman MR: Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism 2003, 52:1287-1294.
38. Djousse L, Ellison RC, Beiser A, Scaramucci A, D'Agostino RB, Wolf PA: Alcohol Consumption and Risk of Ischemic Stroke: The Framingham Study. Stroke 2002, 33:907-912.
39. Djoussé L, Dorgan JF, Zhang Y, Schatzkin A, Hood M, D'Agostino RB, Copenhafer DL, Kreger BE, Ellison RC: Alcohol consumption and risk of lung cancer: the Framingham Study. J Natl Cancer Inst 2002, 94:1877-1882.
40. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, Hennekens C, Stampfer MJ: Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998, 279:359-364.
41. Bazzano LA, He J, Ogden LG, Loria C, Vupputuri S, Myers L, Whelton PK, Kasner SE: Dietary Intake of Folate and Risk of Stroke in US Men and Women: NHANES I Epidemiologic Follow-Up Study ∗ Editorial Comment: NHANES I Epidemiologic Follow-Up Study. Stroke 2002, 33:1183-1189.
42. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998, 316:894-898.
43. Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022.
44. Semmler A, Moskau S, Grigull A, Farmand S, Klockgether T, Smulders Y, Blom H, Zur B, Stoffel-Wagner B, Linnebank M: Plasma folate levels are associated with the lipoprotein profile: a retrospective database analysis. Nutr J 2010, 9:31.
45. Söderström E, Eliasson M, Johnson O, Hallmans G, Weinehall L, Jansson J-H, Hultdin J: Plasma folate, but not homocysteine, is associated with Apolipoprotein A1 levels in a non-fortified population. Lipids Health Dis 2013, 12:74.
46. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, Willett W, Hennekens CH: Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993, 329:1829-1834.
47. Jeppesen J, Schaaf P, Jones C, Zhou MY, Chen YD, Reaven GM: Effects of low-fat, high-carbohydrate diets on risk factors for ischemic heart disease in postmenopausal women. Am J Clin Nutr 1997, 65:1027-1033.
48. Abbasi F, McLaughlin T, Lamendola C, Kim HS, Tanaka A, Wang T, Nakajima K, Reaven GM: High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk. Am J Cardiol 2000, 85:45-48.
49. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R: High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992, 86:803-811.
50. Singh RB, Rastogi SS, Sharma VK, Saharia RB, Kulshretha SK: Can dietary magnesium modulate lipoprotein metabolism? Magnes Trace Elem 1990, 9:255-264.
51. He K: Magnesium Intake and Incidence of Metabolic Syndrome Among Young Adults. Circulation 2006, 113:1675-1682.
52. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC: Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000, 343:16-22.
53. Kromhout D: Prevention of Coronary Heart Disease by Diet and Lifestyle: Evidence From Prospective Cross-Cultural, Cohort, and Intervention Studies. Circulation 2002, 105:893-898.
54. Zock PL, de Vries JH, Katan MB: Impact of myristic acid versus palmitic acid on serum lipid and lipoprotein levels in healthy women and men. Arterioscler Thromb Vasc Biol 1994, 14:567-575.
55. Müller H, Lindman AS, Brantsaeter AL, Pedersen JI: The serum LDL/HDL cholesterol ratio is influenced more favorably by exchanging saturated with unsaturated fat than by reducing saturated fat in the diet of women. J Nutr 2003, 133:78-83.
56. Hu FB, Stampfer MJ, Manson JE, Rimm E, Colditz GA, Rosner BA, Hennekens CH, Willett WC: Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med 1997, 337:1491-1499.
57. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, Ryder JJ, Hall WL, Cassidy A: Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008, 88:38-50.
58. Costa LG, Tait L, Laat R, Dao K, Giordano G, Pellacani C, Cole TB, Furlong CE: Modulation of Paraoxonase 2 (PON2) in Mouse Brain by the Polyphenol Quercetin: A Mechanism of Neuroprotection? Neurochem Res 2013, 38:1809-1818.